CTLA-4 silencing could promote anti-tumor effects in hepatocellular
Authors (first, second and last of 9)
Collection
Mechanisms of resistance to cancer therapy
Metastatic cancer is ultimately resistant to virtually all systemic therapies and continues to kill more than 10 million people per year around the world. This suggests a common mechanism for cancer resistance that evolves in millions of people each year, regardless of the instigating carcinogens, suite of mutations present in the tumor, or the tissue of origin. This therapeutic resistance has classically been attributed to genetic tumor cell heterogeneity that develops by stochastic chance, fueled by aneuploidy and genetic instability. In this classic view, resistance to each different therapy requires that the appropriate mutations that confer the different versions of resistance are acquired by at least one cell. Newer models have found potential evidence for the gradual, multifactorial adaptation to the inhibitors through acquisition of multiple cooperating genetic and epigenetic adaptive changes of multiple partially resistant clones as well as the presence of cancer stem cells in which a rare therapy-resistant population of cancer stem cells give rise to a recurrent, resistant population.
Articles are welcome for this collection “Mechanisms of resistance to cancer therapy” that explore how treatment resistance arises in cancer.
Articles (39 in this collection)
-
-
Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasis
Authors (first, second and last of 6)
-
Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer
Authors (first, second and last of 6)
-
Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights
Authors (first, second and last of 7)
-
Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
Authors (first, second and last of 9)
-
The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study
Authors (first, second and last of 5)
-
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Authors (first, second and last of 4)
-
Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells
Authors (first, second and last of 9)
-
LITAF inhibits colorectal cancer stemness and metastatic behavior by regulating FOXO1-mediated SIRT1 expression
Authors (first, second and last of 6)
-
-
-
-
Identification of miR-4510 as a metastasis suppressor of gastric cancer through regulation of tumor microenvironment via targeting GPC3
Authors (first, second and last of 5)
-
-
A highly annotated database of genes associated with platinum resistance in cancer
Authors (first, second and last of 9)
-
Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine
Authors (first, second and last of 10)
-
NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
Authors (first, second and last of 13)
-
Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
Authors (first, second and last of 4)
-
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
Authors (first, second and last of 17)
-
-
-
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Authors (first, second and last of 4)
-
-
-
Cancer stem cells in colorectal cancer and the association with chemotherapy resistance
Authors (first, second and last of 8)
-
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4
Authors (first, second and last of 5)
-
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
Authors (first, second and last of 5)
-
-
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Authors (first, second and last of 11)
-
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
Authors (first, second and last of 19)
-
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia
Authors (first, second and last of 5)
-
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
Authors (first, second and last of 7)
-
Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
Authors (first, second and last of 5)
-
ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942
Authors (first, second and last of 10)
-
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
Authors (first, second and last of 10)
-
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Authors (first, second and last of 26)
-
The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells
Authors (first, second and last of 12)
-
Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer
Authors (first, second and last of 10)
-
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Authors (first, second and last of 4)
